Laura J. Esserman, MD, MBA, a 2018 Giants of Cancer Care® award winner in the Cancer Diagnostics category led the way in designing the I-SPY clinical trials, a groundbreaking effort to match patients with breast cancer to potential therapies based on molecular drivers of disease. She also has advocated for a greater understanding of the biological drivers of breast cancer, rather than relying on mass screening programs, to better analyze early disease.
During a recent OncLive Peer Exchange®, a panel of breast cancer experts discussed emerging agents in triple-negative breast cancer, which include an anti–PD-L1 antibody, 2 PARP inhibitors, and a novel antibody–drug conjugate.
Earlier diagnosis and more effective therapeutic options are enabling physicians to deliver better rates of disease control and improved quality of life to patients with hormone receptor–positive, HER2-negative metastatic breast cancer.
Massimo Cristofanilli, MD, discusses the clinical utility of liquid biopsies—specifically focusing on circulating tumor cells and cell-free DNA—and highlights ongoing research in the space.
Komal Jhaveri, MD, discusses the 3 major classes of drugs showing potential in the TNBC pipeline.
Denise A. Yardley, MD, discusses key data presented at the 2018 SABCS and the impact of the SOLAR-1 findings.
Howard A. “Skip” Burris, MD, highlights some of the exciting updates from the 2018 San Antonio Breast Cancer Symposium and what can be expected in the breast cancer field in the year ahead.
Stephanie L. Graff, MD, discusses the latest updates on escalation and de-escalation of therapy in patients with HR-positive breast cancer.
Susan Domcheck, MD, discusses the updated results of the MEDIOLA trial in patients with germline BRCA-mutated metastatic breast cancer and speaks to the next phase of development with the combination.
Kevin Kalinsky, MD, MS, highlights the recent data with alpelisib and CDK4/6 inhibitors, the toxicity differences between the 3 available CDK4/6 agents, and the next steps for both classes of agents.